Black Diamond Therapeutics, Inc. Common Stock BDTX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T16:42:13.581Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:42:08.032669061Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T16:42:11.926526+00:00
Black Diamond Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 1.50 | 612.1% | 37.3% | |||
| 35Δ | 2.00 | 610.2% | 34.4% | |||
| 40Δ | 2.49 | 608.3% | 31.6% | |||
| 45Δ | 2.99 | 606.3% | 28.8% | |||
| 50Δ | 3.48 | 604.4% | 25.9% | |||
| 55Δ | 3.98 | 602.5% | 23.1% | |||
| 60Δ | 4.47 | 600.6% | 20.2% | |||
| 65Δ | 1.83 | 624.0% | 48.0% | 4.97 | 598.6% | 17.4% |
| 70Δ | 1.62 | 574.9% | 37.9% | 5.46 | 596.7% | 14.5% |
| 75Δ | 1.42 | 525.8% | 27.7% | 5.96 | 594.8% | 11.7% |
| 80Δ | 1.22 | 476.7% | 17.6% | 6.45 | 592.8% | 8.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.50
- IV
- 612.1%
- B/E move
- 37.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.00
- IV
- 610.2%
- B/E move
- 34.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.49
- IV
- 608.3%
- B/E move
- 31.6%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.99
- IV
- 606.3%
- B/E move
- 28.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.48
- IV
- 604.4%
- B/E move
- 25.9%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.98
- IV
- 602.5%
- B/E move
- 23.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.47
- IV
- 600.6%
- B/E move
- 20.2%
65Δ
- Pseudo strike
- 1.83
- IV
- 624.0%
- B/E move
- 48.0%
- Pseudo strike
- 4.97
- IV
- 598.6%
- B/E move
- 17.4%
70Δ
- Pseudo strike
- 1.62
- IV
- 574.9%
- B/E move
- 37.9%
- Pseudo strike
- 5.46
- IV
- 596.7%
- B/E move
- 14.5%
75Δ
- Pseudo strike
- 1.42
- IV
- 525.8%
- B/E move
- 27.7%
- Pseudo strike
- 5.96
- IV
- 594.8%
- B/E move
- 11.7%
80Δ
- Pseudo strike
- 1.22
- IV
- 476.7%
- B/E move
- 17.6%
- Pseudo strike
- 6.45
- IV
- 592.8%
- B/E move
- 8.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 129.39% | |
| 161.28% | |
| 120.49% | |
| 113.26% | |
| 123.60% | |
| 124.37% | |
| 128.02% | |
| 135.86% | |
| 157.59% | |
| 198.56% | |
| 213.47% | |
| 164.58% | |
| 164.24% | |
| 204.79% | |
| 239.71% | |
| 201.68% | |
| 161.00% | |
| 175.16% | |
| 125.94% | |
| 177.44% | |
| 161.42% | |
| 185.52% | |
| 191.08% | |
| 165.58% | |
| 197.41% | |
| 248.43% | |
| 234.77% | |
| 291.06% | |
| 271.26% | |
| 173.94% | |
| 160.77% | |
| 175.91% | |
| 166.79% | |
| 162.10% | |
| 191.08% | |
| 190.14% | |
| 203.12% | |
| 186.45% | |
| 169.56% | |
| 195.03% |
Biotechnology
BEAM
Description unavailable
More →BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The…
More →BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular…
More →BMEA
Description unavailable
More →BMRN
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San…
More →BNTC
Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.
More →